Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Recruiting

Phase 3

Best Available Therapy vs. Autologous Hematopoietic Stem Cell TransplantBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT04047628

Conditions

Relapsing Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Autologous Hematopoietic Stem Cell Transplantation

Best Available Therapy (BAT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2025-08-29.